coenzyme-q10 and Alopecia

coenzyme-q10 has been researched along with Alopecia* in 4 studies

Trials

1 trial(s) available for coenzyme-q10 and Alopecia

ArticleYear
[Protective effects of coenzyme Q10 on the adverse reactions of anthracycline antibiotics: using double blind method--with special reference to hair loss].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:10

    It was clinically evaluated by double blind method whether co-enzyme Q10 has protective effects on hair loss caused by anthracycline antibiotics. Six cases of acute leukemia, 2 blastic crisis of CML and 11 malignant lymphoma were entered to this study. DCMP regimen for acute leukemia for VEPA for lymphoma were performed. Coenzyme Q10 (or placebo) of 120 mg/day was orally administered. The grade of hair loss was classified into five groups. Five cases were only given to DM and 3 cases receiving DM and CoQ10. ADM was 6 cases and 5 were combined with CoQ10. No significant diffehence in effect of CoQ10 administration rence was recognized between two groups statistically. Elevations of GOT and GPT were less frequent in the group receiving CoQ10.

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Coenzymes; Double-Blind Method; Female; Humans; Leukemia; Male; Middle Aged; Naphthacenes; Ubiquinone

1983

Other Studies

3 other study(ies) available for coenzyme-q10 and Alopecia

ArticleYear
Coenzyme Q10 phospholipidic vesicular formulations for treatment of androgenic alopecia:
    Expert opinion on drug delivery, 2021, Volume: 18, Issue:10

    Coenzyme Q10 (CoQ10) is an antioxidant molecule with anti-aging activity on human hair, and because of its pharmaceutical limitations such as large molecular weight, high lipophilicity and poor water solubility, its therapeutic effectiveness has been hampered. Therefore, different vesicular nanocarriers were developed in the current work, for enhancement of the skin penetration of CoQ10 for treatment of androgenic alopecia.. In order to overcome the poor skin penetration of CoQ10, it was formulated in liposomes, transfersomes, ethosomes, cerosomes and transethosomes using the thin-film hydration method. Results revealed that transethosomes were the carrier of choice for CoQ10, in which it displayed a particle size of 146 nm, zeta potential -55 mV and entrapment efficiency of 97.63%. Transethosomes also achieved the highest deposition percentage for CoQ10, exceeding 95% in the different skin layers. Upon clinical examination in patients suffering from androgenic alopecia, CoQ10 transethosomes displayed better clinical response than the administration of CoQ10 solution, which was further confirmed by dermoscopic examination.. Findings of this study further prove that loading antioxidants such as CoQ10 in nanocarriers maximizes their therapeutic efficiency, and opens many opportunities for their application in treatment of several other topical diseases.

    Topics: Administration, Cutaneous; Alopecia; Drug Compounding; Humans; Skin Absorption; Ubiquinone

2021
Treatment of warfarin-induced hair loss with ubidecarenone.
    Lancet (London, England), 1995, Oct-21, Volume: 346, Issue:8982

    Topics: Alopecia; Anticoagulants; Coenzymes; Female; Humans; Middle Aged; Ubiquinone; Warfarin

1995
[Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:7

    This study was designed to evaluate the usefulness of Coenzyme Q10 (CoQ10) in the prevention of side effects due to anthracycline agents-Adriamycin (ADM) and Daunorubicin (DNR)-by comparing the preventive effect between CoQ10-treated and non-treated groups. The subjects were 79 patients, 55 of whom had malignant lymphoma. The age range was from 16 to 77 years with a mean age of 45.4 years. CoQ10 was administered by intravenous drip at 1 mg/kg/day the day before ADM or DNR administration, on the day and for a further 2 days after administration. In mean total dose, complete remission rate and mortality, no significant differences were observed between the 2 groups. Although there were also no significant differences in the degree of alopecia, fever, nausea and vomiting, the incidences of diarrhea and stomatitis were significantly (p less than 0.10 and p less than 0.05, respectively) reduced in the CoQ10-treated group. Depression of ST waves (more than 0.05 mV) and changes in T waves (R/10 greater than T, flat, inversion) on ECG were regarded as a parameter of aggravation. Such ECG aggravation was found in 20 of 40 patients given CoQ10 (50.0%) and in 18 of 25 receiving none (72.0%); a cardiotoxicity-inhibiting tendency was thus evident (p less than 0.10). In heart rate, tachycardia was noted in the nontreated group when the period of use of anthracycline agents exceeded 8 weeks. Twenty nine patients received ADM or DNR for 8 weeks or more, and, of them, 17 were treated with CoQ10; 11 of the 17 (64.7%) showed ECG aggravation, while 11 of 12 patients (91.7%) not treated with CoQ10 showed ECG aggravation. A tendency to depress ECG aggravation was thus observed in the treated group (p less than 0.10).

    Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Coenzymes; Daunorubicin; Diarrhea; Doxorubicin; Drug Therapy, Combination; Electrocardiography; Female; Fever; Heart Rate; Humans; Leukemia; Male; Middle Aged; Nausea; Stomatitis; Ubiquinone

1984